On July 13, 2026, the FDA approved Leqembi Iqlik, weekly subcutaneous lecanemab-irmb, as a starting dose for early Alzheimer's disease, with no prior 18-month IV course required, according to Eisai and Biogen via the FDA approval notice. People who choose it can give doses at home only after a health professional directly supervises at least two consecutive doses and confirms technique.
Leqembi Iqlik is an amyloid-targeting antibody for early Alzheimer's disease. Early means mild cognitive impairment or mild dementia due to Alzheimer's with confirmed amyloid-beta pathology. Readers should treat at-home as supervised home dosing, not self-starting treatment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Apply through Biospace’s official page — Use this page to review requirements and apply directly.
- Read the official notice from Alz — Use this primary source to verify the official announcement.
Table of Contents
- Who can choose the injection start?
- What does a weekly dose look like?
- What must injection training include?
- How well does the injection work?
- What risk still needs close reading?
Who can choose the injection start?
Adults with mild cognitive impairment or mild dementia due to Alzheimer's and confirmed amyloid-beta pathology may now choose weekly injections or biweekly IV infusions. The choice is between routes for the same treatment path. It is not an expansion to later dementia stages.
Confirmation of amyloid pathology comes before treatment. ApoE testing counseling also remains part of care. These steps shape eligibility and risk discussion with the clinician.
What does a weekly dose look like?
The initiation dose is 500 mg weekly, given as two 250-mg autoinjector injections in about 15 seconds, according to Medscape's dosing summary. Maintenance after 18 months is 360 mg weekly. The lower later dose matters for planning refills and expectations.
Two injections per initiation-day is normal, not a missed dose or extra dose. The short administration time does not shorten training or follow-up. Families should plan a clean setup, a fixed weekly day, and a simple log.
What must injection training include?
FDA labeling requires direct supervision of at least two consecutive doses, plus confirmation that patient or caregiver technique is appropriate, before home use, as summarized by Denkstrom from the FDA label summary. Regular reassessment follows thereafter. Home use begins only after that check is passed.
Eisai and Biogen offer the LEQEMBI Companion program with in-person or virtual Nurse Educators and an app with education and tracking tools. Use the app as a backup, not a substitute for supervised practice. Bring questions about bruising, incomplete injection, device problems, and storage to the educator.
- Give two full initiation doses under direct supervision
- Show preparation, site selection, injection, disposal, and missed-dose steps
- Confirm the caregiver can repeat the process safely without prompts
- Schedule reassessment of technique after home dosing starts
How well does the injection work?
Supportive extension data showed weekly subcutaneous dosing reached about 104% drug exposure versus IV and 14% greater amyloid clearance at six months. That result supports comparable efficacy. Clearance means removal of amyloid-beta plaques seen on imaging.
Comparable does not mean identical for every person. Individual response, missed doses, and side effects still vary. Patients should keep MRI and clinic visits even when injections feel routine.
What risk still needs close reading?
Amyloid-related imaging abnormalities, called ARIA, occurred in 21% with Leqembi versus 9% with placebo, rising to 45% in ApoE-e4 homozygotes, with a boxed warning for severe, life-threatening or fatal ARIA, according to Eisai and Biogen via the safety information in the approval notice. Baseline and follow-up MRIs are required. Genetic risk counseling helps families weigh that warning.
At-home dosing does not remove clinic burden because MRI monitoring, ApoE counseling, and clinician oversight stay central. Initiation supply moved through specialty pharmacies from late August 2026. Ask the prescribing center where MRIs occur, who reviews them, and what symptoms prompt urgent care.
You Might Also Like
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: How People With Early Alzheimer’s Can Read the FDA Headline Carefully
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: How People With Early Alzheimer’s Can Read the FDA Headline Carefully
- MRI and ARIA Monitoring With At-Home Leqembi in 2026: How People With Early Alzheimer’s Can Read the FDA Headline Carefully
